Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer

SIMPLE SUMMARY: There is no established standard second-line chemotherapy after modified FOLFIRINOX for unresectable pancreatic cancer. While gemcitabine plus nab-paclitaxel is often used as second-line chemotherapy after modified FOLFIRINOX, outcomes and prognostic factors of second-line gemcitabin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mie, Takafumi, Sasaki, Takashi, Takeda, Tsuyoshi, Okamoto, Takeshi, Hamada, Tsuyoshi, Ishitsuka, Takahiro, Yamada, Manabu, Nakagawa, Hiroki, Furukawa, Takaaki, Kasuga, Akiyoshi, Matsuyama, Masato, Ozaka, Masato, Sasahira, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857205/
https://www.ncbi.nlm.nih.gov/pubmed/36672308
http://dx.doi.org/10.3390/cancers15020358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857205/
https://www.ncbi.nlm.nih.gov/pubmed/36672308
http://dx.doi.org/10.3390/cancers15020358

Ejemplares similares